Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »
Hepatitis C medication costs in 2015 proved lower for the U.S. than Europe and Japan, particularly prices negotiated by pharmacy benefit managers in Medicare Part D, the Pharmaceutical Care Management Association recently reported. Read More »
As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. Read More »
The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. Read More »
Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. Read More »
A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. Read More »
If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. Read More »
A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. Read More »
A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. Read More »
Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. Read More »
WASHINGTON, D.C. -- Medicare Part D premiums will see only a modest rise in 2017, despite costs to taxpayers growing faster than parts A and B, the Centers for Medicare and Medicaid Services (CMS) recently said in a statement. Read More »
With only the slightest of increases, Medicare recently announced that the average monthly cost for a Medicare Part D prescription drug plan in 2017 is projected to remain reasonably stable at approximately $34. Read More »
Jostling among hospitals, pharmacies, doctors, and third-party payers over the delivery of specialty cancer drugs is likely to intensify, according to experts observing the already fast shifting field of oncology treatment channeling. Read More »
This week, Congress passed the Comprehensive Addiction and Recovery Act (CARA), which aims to combat prescription drug abuse, especially opioids. Read More »
Forcing drug companies to disclose wholesale prices would likely put more pressure on consumers’ wallets, health economist Devon Herrick said. Read More »
Indiana pharmacist Kevin Foster was recently arrested and charged with Filling an Invalid Prescription for Legend Drugs by a Pharmacist, Marion County Prosecuting Attorney Terry Curry announced. Read More »
In keeping with President Obama's budget request, a Senate committee recently approved a request to create a small fee for the 340B drug discount program. Read More »
Pfizer Inc. recently announced its completed acquisition of Anacor Pharmaceuticals, Inc., giving each outstanding Anacor common stock share the opportunity to gain $99.25 net in cash as part of the acquisition. Read More »
American consumers will be able to enjoy the benefits of drug competition that results in more choice and lower prices for life-saving drugs via the newly proposed Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, U.S. Sen. Chuck Grassley (R-Iowa) said. Read More »
A bipartisan bill introduced this week in the Senate would allow generic drug companies to sue the brand-name marketplace giants for samples and safety protocols. Read More »
Alerts Sign-up
